D. Halpin (Devon, United Kingdom), D. Singh (Manchester, United Kingdom)
Late Breaking Abstract - Anti-IL-4 and anti-IL-13 dual vaccination using Kinoid technology prevents development of allergic asthma in mice
E. Conde Garcia (Paris, France), R. Bertrand (Paris, France), B. Balbino (Paris, France), J. Bonnefoy (Paris, France), J. Stackowicz (Paris, France), N. Caillot (Paris, France), F. Colaone (Paris, France), S. Hamdi (Paris, France), P. Bruhns (Paris, France), V. Serra (Paris, France), G. Grouard-Vogel (Paris, France), L. Reber (Paris, France)
|     |
Late Breaking Abstract - Spatial pharmacokinetics of inhaled drugs in human lung – evaluation of regional lung targeting by direct sampling of epithelial lining fluid
M. Sadiq (Gothenburg, Sweden), O. Holz (Hannover, Germany), B. Ellinghusen (Hannover, Germany), C. Faulenbach (Hannover, Germany), M. Müller (Hannover, Germany), P. Badorrek (Hannover, Germany), U. Eriksson (Gothenburg, Sweden), M. Fridén (Gothenburg, Sweden), S. Stomilovic (Gothenburg, Sweden), A. Lundqvist (Gothenburg, Sweden), J. Hohlfeld (Hannover, Germany)
| |
Late Breaking Abstract - Effectiveness and safety of mepolizumab in real-world clinical practice: the REALITI-A study
T. Harrison (Nottingham, United Kingdom), G. Canonica (Milan, Italy), K. Gemzoe (Uxbridge, United Kingdom), A. Maxwell (Stevenage, United Kingdom), S. Yang (Collegeville, United States of America), S. Joksaite (Uxbridge , United Kingdom), R. O’Reilly (Stevenage, United Kingdom), M. Van Dyke (Upper Providence, United States of America), F. Albers (Research Triangle Park, United States of America), N. Kwon (Brentford, United States of America)
| |
Late Breaking Abstract - SABA overuse and risk of mortality in a nationwide Swedish asthma cohort (HERA)
C. Janson (Lund, Sweden), B. Nwaru (Gothenburg, Sweden), L. Hasvold (Södertälje, Sweden), F. Wiklund (Uppsala, Sweden), G. Telg (Södertälje, Sweden), M. Ekström (Lund, Sweden)
| |
Late Breaking Abstract - Dose responses for topical efficacy and systemic activity, dose equivalence and relative therapeutic index for fluticasone furoate (FF), fluticasone propionate (FP) and budesonide (BUD) in asthmatic subjects.
P. Daley-Yates (Uxbridge, United Kingdom), N. Brealey (Uxbridge, United Kingdom), B. Kumar (Bangalore, India), S. Thomas (Bangalore, India), D. Austin (Uxbridge, United Kingdom), S. Shabbir (Stevenage, United Kingdom), T. Harrison (Nottingham, United Kingdom), D. Singh (Manchester, United Kingdom), N. Barnes (Brentford, United Kingdom)
| |
Late Breaking Abstract - Overprescription of short-acting beta2-agonists in asthma management? Pharmacy reports from 91,673 patients in Poland
M. Kupczyk (Lodz, Poland), W. Barg (Wroclaw, Poland), G. Bochenek (Krakow, Poland), G. Brozek (Katowice, Poland), D. Brzostek (Warsaw, Poland), P. Dabrowiecki (Warsaw, Poland), A. Dabrowski (Warsaw, Poland), R. Dobek (Warsaw, Poland), R. Gawlik (Katowice, Poland), A. Kucharczyk (Warsaw, Poland), I. Kuprys-Lipinska (Lodz, Poland), A. Mastalerz-Migas (Wroclaw, Poland), E. Zagrajek (Warsaw, Poland), M. Kowalski (Lodz, Poland)
| |
Late Breaking Abstract - Influence of salbutamol use on symptomatic outcomes with maintenance bronchodilators: a pre-specified analysis of the EMAX trial
F. Maltais (Québec, QC, Canada), I. Naya (Brentford, Middlesex, United Kingdom), E. Kerwin (Medford, OR, United States of America), L. Bjermer (Lund, Sweden), I. Boucot (Brentford, Middlesex, United Kingdom), P. Jones (Brentford, Middlesex, United Kingdom), L. Tombs (Uxbridge, Middlesex, United Kingdom), D. Lipson (Collegeville, PA, United States of America), C. Compton (Brentford, Middlesex, United Kingdom), C. Vogelmeier (Marburg, Germany)
| |